Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
6,796,202
-
Share change
-
+548,924
-
Total reported value
-
$114,938,774
-
Put/Call ratio
-
203%
-
Price per share
-
$16.92
-
Number of holders
-
77
-
Value change
-
+$11,549,832
-
Number of buys
-
42
-
Number of sells
-
27
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2020
As of 30 Sep 2020,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
77 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,796,202 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, Invesco Ltd., NORTHERN TRUST CORP, RAYMOND JAMES & ASSOCIATES, ABNER HERRMAN & BROCK LLC, MORGAN STANLEY, and Nuveen Asset Management, LLC.
This page lists
77
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.